Lung Adenocarcinoma Harboring Concomitant EGFR Mutation and EML4-ALK Fusion That Benefits From Three Kinds of Tyrosine Kinase Inhibitors: A Case Report and Literature Review

作者：Zhao Ning; Zheng Shu yi; Yang Jin ji; Zhang Xu chao; Xie Zhi; Xie Bin; Su Jian; Chen Zhi hong; Chen Shi liang; Zhang Na; Lou Na na; Dong Song; Wu Yi long^*

来源：Clinical Lung Cancer, 2015, 16(2).

DOI：10.1016/j.cllc.2014.11.001

• Concomitant
• Echinoderm microtubule-associated protein-like 4
• Epidermal growth factor receptor
• NSCLC
• Tyrosine kinase inhibitor

The concomitant presence of echinoderm microtubule-associated protein-like 4 anaplastic lymphoma kinase (EML4-ALK) and epidermal growth factor receptor (EGFR) is extremely rare.
Previous studies have shown that EGFR mutation and EML4-ALK fusion are mutually exclusive and that the coexistence of these 2 genes are associated with resistance to EGFR tyrosine kinase inhibitors (TKIs) and ALK inhibitors.
We report a case of lung adenocarcinoma harboring a concomitant EGFR mutation and EML4-ALK fusion that benefited for a short period from 3 TKIs.
Additional study is warranted to clarify the therapeutic strategies in such patients with a concomitant EGFR mutation and EML4-ALK fusion.

• 单位
  广东省人民医院; 南昌大学